Novo Nordisk CagriSema Weight Loss Data: Early Responders Achieve 25.4% Weight Loss at 68 Weeks
nashnova research
Novo Nordisk presented two exploratory analyses from its REDEFINE 1 Phase III trial at ObesityWeek 2026 — early responders on CagriSema lost 25.4% of body weight by week 68, but GI side effects hit nearly 80%. The FDA decision is expected in Q4 2026.
Where does the "25.4%" come from?
67.8% of CagriSema subjects lost 5% or more of body weight by week 8 — qualifying them as "early responders."
By week 68, early responders averaged 25.4% weight loss; slower responders averaged 17.8%.
This means → the drug does not work equally for everyone: nearly seven in ten responded fast and lost more, but the remaining three in ten saw a markedly smaller effect.
Novo Nordisk cautioned that these figures come from on-treatment measurements and should not guide clinical decisions — in plain terms = this is a post-hoc data cut, not a pre-specified endpoint the trial was designed to prove.
Beyond weight, did daily life improve?
73.1% of the CagriSema group reported meaningful improvement in daily physical activity, versus 49.1% on placebo.
For self-esteem and social comfort, 69% in the CagriSema group reported improvement, versus 42.1% on placebo.
This means → the gap between drug and placebo is roughly 20–27 percentage points, with measurable gains on both physical and psychological dimensions.
These estimates assume all subjects completed treatment as planned — real-world dropout would likely narrow the gap.
How serious are the side effects?
79.6% of the CagriSema group experienced gastrointestinal adverse events (nausea, diarrhea, etc.), versus 39.9% on placebo.
In plain terms = roughly four out of every five people on the drug had GI discomfort — a familiar weak spot across today's weight-loss medications.
Discontinuation due to side effects: 5.9% for CagriSema, 3.5% for placebo — a modest difference, meaning most patients stayed on treatment.
This reflects a core tension in the weight-loss drug race: the more potent the drug, the higher the GI side-effect rate tends to be — regulators and the market are both watching where that line falls.
What exactly is CagriSema?
CagriSema is a once-weekly injection combining two active ingredients: cagrilintide — which mimics an appetite-suppressing hormone — and semaglutide, the core compound behind Ozempic and Wegovy.
REDEFINE 1 enrolled adults with obesity or overweight plus related health conditions, but without type 2 diabetes.
This means → the drug targets a "pure weight-loss" population, not diabetes patients who also lose weight — a more focused market position than existing products.
How far is it from market?
CagriSema is not yet approved in the U.S. The FDA decision is expected in Q4 2026.
This means → the clinical data are on the table; the key question now is whether the FDA considers them sufficient for approval.
Both analyses released this time are exploratory — not the confirmatory evidence required for regulatory clearance. In plain terms = they can boost market confidence, but they do not directly determine the approval outcome.
市场有风险,内容仅供研究参考,不构成投资建议。
